Gail K. Naughton, Ph.D., CEO, Chairman of the Board

In addition to being the Dean of the College of Business Administration at San Diego State University since August 2002, Dr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Executive Officer and Chairman of the Board for the Company. She has spent more than 15 years extensively researching the tissue engineering process, holds more than 90 U.S. and foreign patents and has been extensively published in the field. gnaughton@histogeninc.com

During her tenure at Advanced Tissue Sciences, where she was the company's co-founder and co-inventor of its core technology, Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. While serving as an officer and director of the Company, Dr. Naughton oversaw the design and development of the world's first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton sits on the Board of directors of the City of Hope, Celera (NASDAQ: CRA) and CR Bard (NYSE: BCR).

David Nassif, President and CFO

David W. Nassif, J.D. was appointed President and CFO in May 2011. Previously, he was a principal at Strategic Consulting Services, providing high-level management consulting to life sciences companies, including Histogen. He served as the Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Zogenix, Inc. from May 2007 to March 2010 after consulting for Zogenix from October 2006 to May 2007. From May 2006 to October 2006, as well as earlier from 2001 to 2002, Previously, Mr. Nassif served as a principal at Strategic Consulting Services providing capital raising, mergers and acquisitions, licensing and investor relations services to various public and private life science and technology companies.

From 2002 to May 2006, Mr. Nassif was the Chief Financial Officer and Senior Vice President of Global Licensing at Amphastar Pharmaceuticals, Inc., a privately-held, generic and specialty pharmaceutical company. From 2000 to 2001, he was the Senior Vice President and Chief Financial Officer of RealAge, Inc., a privately-held health care database information marketing company. From 1993 to 1999, Mr. Nassif held various positions with Cypros Pharmaceutical Corporation, an American Stock Exchange listed specialty pharmaceutical company, culminating in the position of Senior Vice President and Chief Financial Officer. Mr. Nassif received a B.Sc. in Finance and Management Information Systems from the University of Virginia and a J.D. from the University of Virginia.

Jonathan N. Mansbridge, M.A., Ph.D., Chief Scientific Officer

Jonathan Mansbridge won an Open Scholarship to Trinity College, Cambridge in 1957 and a Senior Scholarship in 1960. He received a double first honours degree in Natural Sciences from Cambridge University in 1961, a PhD in biochemistry in 1964 and an MA in 1965. He was on the faculty at the Biochemistry Department of the University of Queensland from 1965-1981, with sabbaticals at the Beatson Institute, Glasgow (1970) and Stanford (1980).

On moving to the United States in 1981, he took a research post with the Psoriasis Research Institute at Stanford University investigating keratinocyte differentiation and wound healing. Subsequently, from 1986 - 1993 he worked on signal transduction systems in thee-dimensional culture at SRI International and on microvascular endothelial cell physiology in the Department of Dermatology at Stanford University. In 1993, he joined Advanced Tissue Sciences (ATS) as Senior Principal Scientist, subsequently rising to Distinguished Research Fellow. In this position he was extensively involved in the research, development, regulatory and commercial aspects of tissue engineering, with particular emphasis on the three-dimensional culture of fibroblasts. He was extensively involved in the development, characterization and investigation of TransCyteR for burn wounds and DermagraftR for diabetic foot ulcers. He contributed a great deal to our understanding of the mechanisms of action of these devices in the treatment of acute and chronic wounds. These projects developed into the general employment of tissue-engineered human extracellular matrix for surgical applications. He was the only member of the research ream transferred to Smith and Nephew when they took over the facility from ATS. There he worked on the development of new processes and products based on three-dimensional fibroblast culture. In 2008, he joined Histogen Inc to oversee the development of the hair restoration product (subsequently termed Hair Restoration Complex [HSC]). Subsequently he accepted the position of Chief Scientific Officer to direct the overall research activities of the company. He is the author of more than 250 publications and 4 patents.

Mark Baumgartner, Director of Engineering

Mr. Baumgartner joined the company in 2007 with more than 20 years experience in product and process development for regulated biologic products. During 2006 and 2007 Mr. Baumgartner worked as a consultant to the biomedical and biopharmaceutical sectors on several projects for product development and process engineering. Mr. Baumgartner worked as Director of Process Development for Smith-Nephew Wound Management LLC, producing biological medical device products from 2002 to 2006. mbaumgartner@histogeninc.com

In the same position, Mr. Baumgartner worked at Advanced Tissues Sciences Inc. from 1992 overseeing product and bioprocess development for the companies first in class engineered tissue products. From 1985 to 1992, Mr. Baumgartner managed process development, biochemical engineering and manufacturing functions at Centocor Inc, a diagnostics and biopharmaceutical manufacturer, and Invitron Co., a biologics CMO. His prior experience includes project engineering and management roles for Monsanto Co and Davy-McKee Corp. He earned an A.S. degree in Mechanical Engineering Technology from Mineral Area College.

Dr. Mark A. Hubka, Director of Clinical Affairs

Dr. Hubka brings more than 25 years of clinical experience from the fields of orthopedics and sports medicine to Histogen. His experience in managed care includes his time as State Director of the largest designated provider network (DPN) in California, focused on worker's compensation. mhubka@histogeninc.com

Dr. Hubka has specialized in cost containment in healthcare, consulting for large employers such as Rohr Industries and the San Diego Union Tribune, as well as City and County agencies including San Diego, Santa Barbara and San Francisco. Dr. Hubka previously acted as a consultant to labor councils as well as unions, and has worked with the insurance industry, defense and applicant attorneys. Dr. Hubka also was the Physician Administrator at an out-patient orthopedic surgery center, where he helped to interface with the surgeons and their staff. While in that position, Dr. Hubka handled quality controls and outcome assessments which made for a natural transition to the regenerative medicine field, particularly relating to clinical trials. Dr. Hubka currently sits on the National Licensing Board and does private consulting to college and professional athletes.

Eileen Naughton Brandt, Director of Corporate Communications

Eileen brings more than 5 years of experience in communications and public relations to Histogen. Prior to joining Histogen in 2007, she held positions with Moore Media Relations, Inc., a firm working with high-technology companies throughout the U.S. on various PR projects, with a focus on media relations. Previously, Eileen held positions at San Diego State University's Entrepreneurial Management Center, beginning as a Student Assistant at the San Diego State University and later serving as Program Coordinator. ebrandt@histogeninc.com

Eileen earned her bachelor's degree in Communications - Public Relations from San Diego State University. She is a member of the High Tech Marketing Alliance (HTMA) and the National Communication Association (NCA).

Emmett Pinney B.S., M.S., Director of Oncology & Special Projects

In addition to degrees in Microbiology and Bioengineering, Emmett brings 35 years of laboratory experience to Histogen, including 10 years in Research & Development for Advanced Tissue Sciences where he was instrumental in developing some of their most successful products as well as supervising the internship program. Emmett holds 6 domestic and international patents, and has authored 25 peer reviewed articles. He was also the Co-Founder and CSO of a small profitable biotech company, Intella, L.L.C. epinney@histogeninc.com

Michael P. Zimber, Ph.D., Director of Applied Research

Dr. Michael Zimber brings to Histogen over 15 years of diverse experience in the biotechnology and pharmaceutical industry with a multi-disciplinary background in early phase discovery, preclinical development and translational phases of therapeutic development. He began his scientific career studying developmental biology conducting research on tissue pattern formation and amphibian limb regeneration. mzimber@histogeninc.com

At Synbiotics Corp, he worked on creating monoclonal antibody-based protein therapeutics, and later joined the bioengineering group, which subsequently became UniSyn Technologies, designing, constructing and optimizing hollow fiber mammalian cell bioreactor systems. His capability for cell and tissue engineering was demonstrated at Advance Tissue Sciences (ATS) where he developed and characterized bioengineered tissue-polymer constructs for human therapeutic applications. During his tenure at ATS, he successfully created novel in vitro techniques and bioreactor systems to generate a human dermal equivalent, Dermagraft®, which was approved and commercialized for a variety of human clinical conditions. Also while at ATS, he lead the development of three-dimensional, tissue engineered articular cartilage, vascular, central nervous system, and dermal-epithelial tissue constructs. He continued these interests at Desmos Inc., by producing methods of pancreatic beta cell isolation and growth using novel extracellular matrix products. In addition to his in vitro expertise, Dr. Zimber has extensive preclinical experience in regenerative medicine gained as a Scientist and Director of Preclinical Modeling at Acorda Therapeutics. In these roles, he oversaw the research laboratory and projects while conducting preclinical safety and efficacy trials of small molecule and biological therapeutics using experimental models of spinal cord injury, stroke, heart failure and cardiovascular disease. Dr. Zimber received a Ph.D. in neuroscience from Washington State University, and a B.S. in biological sciences from the University of Illinois at Urbana-Champaign. He is the inventor on several patents, and has numerous peer-reviewed publications and presentations in regenerative medicine, cell biology and neuroscience. He is affiliated with several professional societies including the American Society for Cell Biology, the Society for Neuroscience, National Neurotrauma Society, and Society for Regenerative Medicine.